336 related articles for article (PubMed ID: 32801341)
21. Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia.
Meserve EE; Strickland KC; Miron A; Soong TR; Campbell F; Howitt BE; Crum CP
Int J Gynecol Pathol; 2019 Sep; 38(5):443-448. PubMed ID: 29901519
[TBL] [Abstract][Full Text] [Related]
22. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
23. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
[TBL] [Abstract][Full Text] [Related]
24. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
26. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.
Kuhn E; Meeker A; Wang TL; Sehdev AS; Kurman RJ; Shih IeM
Am J Surg Pathol; 2010 Jun; 34(6):829-36. PubMed ID: 20431479
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
28. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
[TBL] [Abstract][Full Text] [Related]
29. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
30. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
31. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
32. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
[TBL] [Abstract][Full Text] [Related]
33. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
34. Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.
Singh N; Faruqi A; Kommoss F; McCluggage WG; Trevisan G; Senz J; Lum A; Gilks CB; Anglesio M
Mod Pathol; 2018 Apr; 31(4):652-659. PubMed ID: 29148539
[TBL] [Abstract][Full Text] [Related]
35. High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.
Hatano Y; Fukuda S; Makino H; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2018 Apr; 13(1):24. PubMed ID: 29703236
[TBL] [Abstract][Full Text] [Related]
36. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Kim J; Coffey DM; Ma L; Matzuk MM
Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
[TBL] [Abstract][Full Text] [Related]
37. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
38. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
40. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
